The artificial cell design: liposomes - Artificial Cells, Cell Engineering and Therapy - page 93

ability of liposomes to retain a drug at the site of administration and their
bioadhesive properties means that their use is not restricted to the intravenous
route.
Therefore, it is to be expected that commercial products able to improve the
efficacy of both established drugs and new molecules will soon be available. As
well as therapeutic systems, liposomes associated with contrast agents, ferro-
fluids or radioisotopes could be useful diagnostic agents. Finally, specifically
targeted systems could be appropriate tools for ex-vivo cellular therapy.

3.6 Sources of further information and advice

Liposome Technology, Third Edition (2007). Edited by G Gregoriadis, Informa
Healthcare US Inc., New York. A three-volume topic covering all aspects of
liposome formulation in a practical approach.
Methods in Enzymology, Volume 391 (2005) Liposomes, edited by N Duzgunes.
25 articles written by experts in the field.
Andresen T L, Jensen S S and Jorgensen K (2005), `Advanced strategies in
liposomal cancer therapy: problems and prospects of active and tumor
specific drug release', Progress in Lipid Research, vol. 44, pp. 68±97. A
review that concentrates on liposome-mediated drug delivery to tumour cells.

3.7 References
Agrawal A J, Agrawal A, Pal A, Guru P Y and Gupta C M (2002), `Superior chemo-
therapeutic efficacy of Amphotericin B in tuftsin-bearing liposomes against
Leishmania donovani infection in hamsters', J Drug Target, 10, 41±45.
Allen T M and Chonn A (1987), `Large unilamellar liposomes with low uptake into the
reticulo-endothelial system', FEBS Lett, 223, 42±46.
Allen T M and Moase E H (1996), `Therapeutic opportunities for targeted liposomal drug
delivery', Adv Drug Deliv Rev, 21, 117±133.
Allen T M, Lopes de Menezes D, Hansen C B and Moase E H (1998), `Stealth TM
liposomes for the targeting of drugs in cancer', in Gregoriadis G and McCormack
B, Targeting of Drugs 6: Strategies for Stealth Therapeutic Systems, New York,
Plenum Press, 61±75.
Allen T M, Mumbengegwi D R and Charrois G J R (2005), `Anti-CD19-targeted
liposomal doxorubicin improves the therapeutic efficacy in murine B-cell
lymphoma and ameliorates the toxicity of liposomes with varying drug release
rates', Clin Cancer Res, 11 (9), 3567±3573.
Alonso-Romanowski S, Chiaramoni N S, Lioy V S, Gargini R A, Viera L I and Taira M C
(2003), `Characterization of diacetylenic liposomes as carriers for oral vaccines',
Chem Phys Lipids, 122, 191±203.
Anabousi S, Laue M, Lehr C-M, Bakowsky U and Ehrhardt C (2005), `Assessing
transferrin modification of liposomes by atomic force microscopy and transmission
electron microscopy', Eur J Pharm Biopharm, 60, 295±303.
Andresen T L, Jensen S S and Jorgensen K (2005), `Advanced strategies in liposomal
cancer therapy: problems and prospects of active and tumor specific drug release',